Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Clindamycin phosphate [USAN:USP:JAN]
RN: 24729-96-2
UNII: EH6D7113I8
InChIKey: UFUVLHLTWXBHGZ-MGZQPHGTSA-N

Classification Codes

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibacterial
  • Drug / Therapeutic Agent
  • Human Data
  • Reproductive Effect

Molecular Formula

  • C18-H34-Cl-N2-O8-P-S

Molecular Weight

  • 504.9656
 

Names and Synonyms

Name of Substance

  • Clindamycin phosphate
  • Clindamycin phosphate [USAN:USP:JAN]

Synonyms

  • 7(S)-Chloro-7-deoxylincomycin 2-phosphate
  • Cleocin
  • Cleocin phosphate
  • Cleocin phosphate in dextrose 5% in plastic container
  • Cleocin T
  • Clinda-Derm
  • Clindagel
  • Clindamax
  • Clindamycin 2-phosphate
  • Clindamycin dihydrogenphosphat
  • Clindamycin injection
  • Clindamycin phosphate
  • Clindamycin phosphate in dextrose 5%
  • Clindamycin phosphate in dextrose 5% in plastic container
  • Clindamycin-2-dihydrogenphosphat
  • Clindamycin-2-phosphate
  • Clindesse
  • Clindets
  • Dalacin P
  • EINECS 246-433-0
  • Evoclin
  • Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-(dihydrogen phosphate)
  • Sobelin
  • U 28508
  • U-28,508
  • UNII-EH6D7113I8

Systematic Names

  • L-threo-alpha-D-galacto-Octapyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-
  • Methyl (2S-trans)-7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside, 2-(dihydrogen phosphate)

Registry Numbers

CAS Registry Number

  • 24729-96-2

FDA UNII

  • EH6D7113I8

System Generated Number

  • 0024729962

Structure Descriptors

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

InChIKey

UFUVLHLTWXBHGZ-MGZQPHGTSA-N

Smiles

CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)OP(=O)(O)O)O)O)[C@H](C)Cl

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intramuscular 1100mg/kg (1100mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
mouse LD50 intraperitoneal 784mg/kg (784mg/kg)   Drugs under Experimental and Clinical Research. Vol. 3, Pg. 79, 1977.
mouse LD50 intravenous 820mg/kg (820mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
mouse LD50 oral 2539mg/kg (2539mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
mouse LD50 subcutaneous 1036mg/kg (1036mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
rat LD50 intramuscular > 3500mg/kg (3500mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983.
rat LD50 intraperitoneal 745mg/kg (745mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
rat LD50 intravenous 321mg/kg (321mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
rat LD50 oral 1832mg/kg (1832mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Toxicology and Applied Pharmacology. Vol. 27, Pg. 308, 1974.
rat LD50 subcutaneous 3861mg/kg (3861mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
women TDLo intravenous 12mg/kg (12mg/kg) VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

CARDIAC: OTHER CHANGES
Southern Medical Journal. Vol. 75, Pg. 768, 1982.